Free insulin‐like growth factor (IGF)‐1 and IGF‐binding proteins‐2 and ‐3 in serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients

Background:  The insulin‐like growth factor‐1 (IGF‐1) signaling system is regulated by many factors which interact in regulating the bioavailability of IGF‐I. In this context, little information is available on free IGF‐1, the bioactive form of IGF‐1, in amyotrophic lateral sclerosis (ALS).

[1]  C. Howe,et al.  SUBCUTANEOUS IGF-1 IS NOT BENEFICIAL IN 2-YEAR ALS TRIAL , 2009, Neurology.

[2]  M. Tuszynski,et al.  IGF-I gene delivery promotes corticospinal neuronal survival but not regeneration after adult CNS injury , 2009, Experimental Neurology.

[3]  M. Ranke,et al.  Multidimensional reference regions for IGF-I, IGFBP-2 and IGFBP-3 concentrations in serum of healthy adults. , 2008, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[4]  P. Jakeman,et al.  Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis. , 2007, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[5]  G. Brabant,et al.  Normal levels of serum IGF-I: determinants and validity of current reference ranges , 2007, Pituitary.

[6]  I. Rudan,et al.  Comparison of the growth hormone, IGF‐1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls , 2006, European journal of neurology.

[7]  W. Robberecht,et al.  The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. , 2006, Biochimica et biophysica acta.

[8]  Elena S. Di Martino,et al.  Growth hormone secretion is impaired in amyotrophic lateral sclerosis , 2006, Clinical endocrinology.

[9]  G. Fuller,et al.  An Interaction between Insulin-like Growth Factor-binding Protein 2 (IGFBP2) and Integrin α5 Is Essential for IGFBP2-induced Cell Mobility* , 2006, Journal of Biological Chemistry.

[10]  N. Åberg,et al.  Aspects of Growth Hormone and Insulin-Like Growth Factor-I Related to Neuroprotection, Regeneration, and Functional Plasticity in the Adult Brain , 2006, TheScientificWorldJournal.

[11]  R. Norton,et al.  IGF-binding proteins – the pieces are falling into place , 2005, Trends in Endocrinology & Metabolism.

[12]  S. Vanhatalo,et al.  Cerebrospinal fluid insulin‐like growth factor‐1, insulin growth factor binding protein‐2 or nitric oxide are not increased in MS or ALS , 2004, Acta neurologica Scandinavica.

[13]  I. Torres-Aleman,et al.  Role of insulin-like growth factor I signaling in neurodegenerative diseases , 2004, Journal of Molecular Medicine.

[14]  T. Siddique,et al.  Presence of dendritic cells, MCP‐1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue , 2004, Annals of neurology.

[15]  I. Torres-Aleman,et al.  Glutamate excitotoxicity attenuates insulin-like growth factor-i prosurvival signaling , 2003, Molecular and Cellular Neuroscience.

[16]  R. Vos,et al.  Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis , 2003, The Lancet.

[17]  T. Munsat,et al.  Serum insulin-like growth factor-I (IGF-I) does not correlate positively with isometric strength, fatigue, and quality of life in post-polio syndrome , 2001, Journal of the Neurological Sciences.

[18]  W. Pan,et al.  Interactions of IGF-1 with the Blood-Brain Barrier in vivo and in situ , 2000, Neuroendocrinology.

[19]  R. Baxter.  Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. , 2000, American journal of physiology. Endocrinology and metabolism.

[20]  I. Torres-Aleman,et al.  Circulating Insulin-Like Growth Factor I Mediates Effects of Exercise on the Brain , 2000, The Journal of Neuroscience.

[21]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[22]  D. Sautereau,et al.  Nutritional status is a prognostic factor for survival in ALS patients , 1999, Neurology.

[23]  R. Dantzer,et al.  A new mechanism of neurodegeneration: a proinflammatory cytokine inhibits receptor signaling by a survival peptide. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Fattori,et al.  Mucus of the human olfactory epithelium contains the insulin-like growth factor-I system which is altered in some neurodegenerative diseases , 1999, Brain Research.

[25]  N. Yanagisawa,et al.  Nutritional management in amyotrophic lateral sclerosis: a worldwide perspective , 1998, Journal of Neurology.

[26]  V. Barrios,et al.  The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis , 1998, Neurology.

[27]  J. Ma,et al.  The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies , 1995, Journal of the Neurological Sciences.

[28]  D. Rudman,et al.  Prevalence of Low Plasma IGF‐I in Poliomyelitis Survivors , 1993, Journal of the American Geriatrics Society.

[29]  T. Munsat,et al.  Recombinant growth hormone treatment of amyotrophic lateral sclerosis , 1993, Muscle & nerve.

[30]  S. E. Knowles,et al.  Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I in rats. , 1991, The Journal of endocrinology.

[31]  E. Denys,et al.  Somatomedin-C is not increased in the serum of patients with amyotrophic lateral sclerosis. , 1988, Muscle & nerve.

[32]  G. Braunstein,et al.  Serum insulin-like growth factor-I levels in amyotrophic lateral sclerosis. , 1987, Journal of neurology, neurosurgery, and psychiatry.

[33]  S H Appel,et al.  A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and alzheimer disease , 1981, Annals of neurology.

[34]  G. Borasio,et al.  Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. , 2002, The Cochrane database of systematic reviews.